Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension.

Delea, Thomas E; Taneja, Charu; Moynahan, Aaron; Thomas, Simu K; Frech-Tamas, Feride; Oster, Gerry

Delea, Thomas E; Taneja, Charu; Moynahan, Aaron; Thomas, Simu K; Frech-Tamas, Feride; Oster, Gerry.

Affiliation

Delea TE; Policy Analysis Inc., Brookline, MA 02245, USA. tdelea@pai2.com

Am J Health Syst Pharm ; 64(11): 1187-96, 2007 Jun 01.

Article in En | MEDLINE | ID: mdl-17519461

Subject(s)

Antihypertensive Agents/therapeutic use; Cardiovascular Diseases/prevention & control; Hypertension/drug therapy; Kidney Diseases/prevention & control; Lisinopril/therapeutic use; Metoprolol/therapeutic use; Tetrazoles/therapeutic use; Valine/analogs & derivatives; Antihypertensive Agents/administration & dosage; Cardiovascular Diseases/physiopathology; Delayed-Action Preparations; Female; Humans; Insurance Claim Review; Kidney Diseases/physiopathology; Male; Metoprolol/administration & dosage; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Valine/therapeutic use; Valsartan

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Tetrazoles / Valine / Cardiovascular Diseases / Lisinopril / Hypertension / Kidney Diseases / Metoprolol / Antihypertensive Agents Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Am J Health Syst Pharm Journal subject: FARMACIA / HOSPITAIS Year: 2007 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links